Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Citius Pharmaceuticals IncTrade
Vanguard International High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Vanguard International High Dividend Yield ETF trades at $104.49. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRVYMI
Market Cap
$20.01M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$105.05
52-Week Low
$0.48$82.92
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Vanguard International High Dividend Yield ETF

VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.59 with a neutral daily change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral to slightly overbought. The fund has gained attention for its income appeal, with a 3.4% dividend yield and strong performance, including a 55% total return since prior coverage, as noted by Seeking Alpha on 2026-08-02. Recent institutional buying, such as by Barry Investment Advisors on 2026-08-10, underscores confidence.

The outlook is positive, driven by global diversification and high dividend growth, with Vanguard projecting international stocks to outperform U.S. equities over the next decade. Risks include currency fluctuations and economic volatility in international markets. Analyst sentiment is bullish, supported by the fund's defensive yield and institutional inflows.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Vanguard International High Dividend Yield ETF

VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.

Read more on VYMI